Published in Lung Cancer on December 01, 2001
TP53 status and response to treatment in breast cancers. J Biomed Biotechnol (2011) 0.99
Molecular Markers with Predictive and Prognostic Relevance in Lung Cancer. Lung Cancer Int (2012) 0.78
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet (2007) 8.08
Escherichia coli DnaJ and GrpE heat shock proteins jointly stimulate ATPase activity of DnaK. Proc Natl Acad Sci U S A (1991) 5.96
The dnaK protein modulates the heat-shock response of Escherichia coli. Cell (1983) 5.53
Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer (2001) 5.36
Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck (2005) 4.27
The dnaK protein of Escherichia coli possesses an ATPase and autophosphorylating activity and is essential in an in vitro DNA replication system. Proc Natl Acad Sci U S A (1983) 3.96
The E. coli dnaK gene product, the hsp70 homolog, can reactivate heat-inactivated RNA polymerase in an ATP hydrolysis-dependent manner. Cell (1990) 3.51
Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res (1999) 3.15
The HtrA (DegP) protein, essential for Escherichia coli survival at high temperatures, is an endopeptidase. J Bacteriol (1990) 3.14
The nucleotide sequence of the Escherichia coli K12 dnaJ+ gene. A gene that encodes a heat shock protein. J Biol Chem (1986) 3.04
Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM). Ann Oncol (2010) 3.00
Purification and properties of the Escherichia coli dnaK replication protein. J Biol Chem (1984) 2.92
The NH2-terminal 108 amino acids of the Escherichia coli DnaJ protein stimulate the ATPase activity of DnaK and are sufficient for lambda replication. J Biol Chem (1994) 2.85
Purification and properties of the dnaJ replication protein of Escherichia coli. J Biol Chem (1985) 2.84
Isolation and characterization of ClpX, a new ATP-dependent specificity component of the Clp protease of Escherichia coli. J Biol Chem (1993) 2.83
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer (2005) 2.71
The DnaK chaperone modulates the heat shock response of Escherichia coli by binding to the sigma 32 transcription factor. Proc Natl Acad Sci U S A (1992) 2.63
The ClpX heat-shock protein of Escherichia coli, the ATP-dependent substrate specificity component of the ClpP-ClpX protease, is a novel molecular chaperone. EMBO J (1995) 2.63
Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst (2000) 2.56
Escherichia coli grpE gene codes for heat shock protein B25.3, essential for both lambda DNA replication at all temperatures and host growth at high temperature. J Bacteriol (1986) 2.55
The Escherichia coli DnaK chaperone, the 70-kDa heat shock protein eukaryotic equivalent, changes conformation upon ATP hydrolysis, thus triggering its dissociation from a bound target protein. J Biol Chem (1991) 2.47
Role of the Escherichia coli DnaK and DnaJ heat shock proteins in the initiation of bacteriophage lambda DNA replication. Proc Natl Acad Sci U S A (1988) 2.42
A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol (1999) 2.32
Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol (1997) 2.19
Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J (2010) 2.08
Biological role and regulation of the universally conserved heat shock proteins. J Biol Chem (1991) 1.97
Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol (2007) 1.96
Third consensus on medical treatment of metastatic breast cancer. Ann Oncol (2009) 1.96
A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol (2011) 1.88
Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol (1999) 1.74
Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma. Eur Respir J (2011) 1.74
Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. Ann Oncol (2011) 1.73
Structure-function analysis of the zinc finger region of the DnaJ molecular chaperone. J Biol Chem (1996) 1.72
The conserved G/F motif of the DnaJ chaperone is necessary for the activation of the substrate binding properties of the DnaK chaperone. J Biol Chem (1995) 1.71
Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol (2004) 1.71
Isolation and characterization of dnaJ null mutants of Escherichia coli. J Bacteriol (1990) 1.70
Altered HOX and WNT7A expression in human lung cancer. Proc Natl Acad Sci U S A (2000) 1.69
Allelic loss on chromosome 18q as a prognostic marker in stage II colorectal cancer. Gastroenterology (1998) 1.69
Quality of life during chemotherapy in non-small cell lung cancer patients. Acta Oncol (1989) 1.68
Initiation of DNA replication on single-stranded DNA templates catalyzed by purified replication proteins of bacteriophage lambda and Escherichia coli. Proc Natl Acad Sci U S A (1985) 1.59
Physical interactions between bacteriophage and Escherichia coli proteins required for initiation of lambda DNA replication. J Biol Chem (1990) 1.59
Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol (1999) 1.58
Both the Escherichia coli chaperone systems, GroEL/GroES and DnaK/DnaJ/GrpE, can reactivate heat-treated RNA polymerase. Different mechanisms for the same activity. J Biol Chem (1993) 1.58
Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol (2006) 1.58
Recognition, targeting, and hydrolysis of the lambda O replication protein by the ClpP/ClpX protease. J Biol Chem (1999) 1.55
Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann Oncol (2005) 1.51
Endobronchial ultrasound-guided transbronchial needle aspiration for identifying EGFR mutations. Eur Respir J (2009) 1.51
Escherichia coli DnaK protein possesses a 5'-nucleotidase activity that is inhibited by AppppA. J Bacteriol (1986) 1.46
Co-chaperones Bag-1, Hop and Hsp40 regulate Hsc70 and Hsp90 interactions with wild-type or mutant p53. EMBO J (2001) 1.42
Divergent effects of ATP on the binding of the DnaK and DnaJ chaperones to each other, or to their various native and denatured protein substrates. J Biol Chem (1995) 1.41
[Experience with 150 subcutaneous venous reservoirs for venous access and infusion for the treatment of adult patients with oncologic and hematologic disorders and acquired immunodeficiency syndrome]. Med Clin (Barc) (1992) 1.40
The Clp ATPases define a novel class of molecular chaperones. Mol Microbiol (1996) 1.40
[Significance of heterozygosity loss in the long arm of chromosome 5 (5q21) in small cell carcinoma of the lung]. Med Clin (Barc) (1997) 1.39
Second consensus on medical treatment of metastatic breast cancer. Ann Oncol (2006) 1.37
Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers. Cancer Res (2001) 1.34
Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br J Cancer (2009) 1.33
DNA base modifications in chromatin of human cancerous tissues. FEBS Lett (1992) 1.32
Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study. Eur J Cancer (2011) 1.27
Bacteriophage lambda replication proteins: formation of a mixed oligomer and binding to the origin of lambda DNA. Mol Gen Genet (1984) 1.27
Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer. Br J Cancer (2012) 1.24
Enzymology of the pre-priming steps in lambda dv DNA replication in vitro. J Biol Chem (1987) 1.23
Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol (2005) 1.21
Initiation of lambda DNA replication. The Escherichia coli small heat shock proteins, DnaJ and GrpE, increase DnaK's affinity for the lambda P protein. J Biol Chem (1993) 1.20
Guidelines on the standards for the training of specialised health professionals dealing with breast cancer. Eur J Cancer (2007) 1.20
Upper extremity deep venous thrombosis in cancer patients with venous access devices--prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost (1996) 1.17
Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine. Br J Cancer (2008) 1.12
Structural and functional relationships in DnaK and DnaK756 heat-shock proteins from Escherichia coli. J Biol Chem (1992) 1.12
Oxidative DNA base damage and antioxidant enzyme activities in human lung cancer. FEBS Lett (1994) 1.12
Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol (2003) 1.11
ATP hydrolysis is required for the DnaJ-dependent activation of DnaK chaperone for binding to both native and denatured protein substrates. J Biol Chem (1995) 1.10
Amplification of c-myc gene and overexpression of c-Myc protein in breast cancer and adjacent non-neoplastic tissue. Clin Biochem (2001) 1.10
BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer. Ann Oncol (2010) 1.07
ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen. Br J Cancer (2008) 1.06
Oxygen-derived free radicals in cerulein-induced acute pancreatitis. Scand J Gastroenterol (1988) 1.04
Lack of transmission of porcine circovirus type 2 to weanling pigs by feeding them spray-dried porcine plasma. Vet Rec (2008) 1.04
First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study. Ann Oncol (2005) 1.03
Founder BRCA1 mutations and two novel germline BRCA2 mutations in breast and/or ovarian cancer families from North-Eastern Poland. Hum Mutat (2000) 1.03
Molecular genetic abnormalities in premalignant lung lesions: biological and clinical implications. Eur J Cancer Prev (2001) 1.02
The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. Ann Oncol (2007) 1.02
Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients. clinical outcomes and oncologists' preferences. Eur J Cancer (2003) 1.02
Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies. Ann Oncol (2014) 1.01
Complications of breast-cancer radiotherapy. Clin Oncol (R Coll Radiol) (2006) 1.01
Real time kinetics of the DnaK/DnaJ/GrpE molecular chaperone machine action. J Biol Chem (1996) 1.01
The -675 4G/5G plasminogen activator inhibitor-1 promoter polymorphism in house dust mite-sensitive allergic asthma patients. Allergy (2006) 1.01
Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials. Ann Oncol (2011) 1.01
Porcine epidemic abortion and respiratory syndrome (mystery swine disease). Isolation in Spain of the causative agent and experimental reproduction of the disease. Vet Microbiol (1992) 1.01
DjlA is a third DnaK co-chaperone of Escherichia coli, and DjlA-mediated induction of colanic acid capsule requires DjlA-DnaK interaction. J Biol Chem (2000) 1.01
Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. Lung Cancer (2011) 1.01
Pretreatment minimal staging and prognostic factors for non-small cell lung cancer. Lung Cancer (1997) 1.01
Overexpression of cathepsin B correlates with angiogenesis in colon adenocarcinoma. Neoplasma (2004) 1.00
Structure-function analysis of the zinc-binding region of the Clpx molecular chaperone. J Biol Chem (2001) 0.98
Risk factors and prognostic indicators of bacterial meningitis in a cohort of 3580 postneurosurgical patients. Scand J Infect Dis (2001) 0.97
Acute myeloid leukemia with translocation (8;16)(p11;p13) and MYST3-CREBBP rearrangement harbors a distinctive microRNA signature targeting RET proto-oncogene. Leukemia (2012) 0.96
Molecular epidemiology of a large classical swine fever epidemic in the European Union in 1997-1998. Vet Microbiol (2000) 0.96
Structure-function analysis of the Escherichia coli GrpE heat shock protein. EMBO J (1996) 0.95
Prognostic molecular markers in non-small cell lung cancer. Lung Cancer (2001) 0.95
Hsp70 molecular chaperones are required to support p53 tumor suppressor activity under stress conditions. Oncogene (2009) 0.94